TY -的T1 -糖尿病与遗传型的耐药结核病JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01891 -2019欧元SP - 1901891 AU Ruesen Carolien盟——Chaidir Lidya盟——Ugarte-Gil塞萨尔AU - van Ingen Jakko AU -奎奇立朱莉娅·a . AU -希尔,菲利普•c . AU - Ruslami Rovina盟——Santoso Prayudi AU - Huynen,卡坦a . AU - Dockrell淡褐色m . AU -摩尔,大卫A.J.盟——Alisjahbana Bachti AU - van Crevel,来自Y1 - 2019/01/01 UR - //www.qdcxjkg.com/content/early/2019/11/19/13993003.01891 - 2019. -抽象N2 -糖尿病与肺结核(TB)治疗的失败,但目前尚不清楚这是与基因型耐药性的感染分枝杆菌。我们使用全基因组测序(WGS)检查1365种已知耐药性突变在896年结核分枝杆菌分离株的结核病患者筛查糖尿病使用糖化血红蛋白测试作为串联的一部分项目[1]。伦理批准是来自伦敦卫生和热带医学学院和机构审查委员会在印度尼西亚和秘鲁。在秘鲁我们选择所有可用的串联患者结核分枝杆菌分离株(44和445名无糖尿病),和在印尼我们选择所有可用的隔离从糖尿病患者(n = 115) +隔离与非糖尿病病人的一个子集(n = 292)的诊所,在同一时期,由年龄相匹配。我们使用结核病分析器版本0.3.8[2]决定结核分枝杆菌血统和耐药性。构造发展史是使用PhyML version 3.0[3],和最小的两两距离隔离分开计算,没有糖尿病患者,根据国家分层。我们检查如果糖尿病与对个人与耐多药结核病药物或基因型耐药性两国分别结合,多层次多变量逻辑回归,考虑到原产国和调整了年龄,性别,艾滋病毒感染,先前的结核病治疗,结核分枝杆菌血统。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。请打开或下载PDF查看这篇文章。Conflict of interest: Dr. Ruesen has nothing to disclose.Conflict of interest: Dr. Chaidir has nothing to disclose.Conflict of interest: Dr. Ugarte-Gil has nothing to disclose.Conflict of interest: Dr. van Ingen has nothing to disclose.Conflict of interest: Dr. Critchley has nothing to disclose.Conflict of interest: Dr. Hill has nothing to disclose.Conflict of interest: Dr. Ruslami has nothing to disclose.Conflict of interest: Dr. Santoso has nothing to disclose.Conflict of interest: Dr. Huynen has nothing to disclose.Conflict of interest: Dr. Dockrell has nothing to disclose.Conflict of interest: Dr. Moore has nothing to disclose.Conflict of interest: Dr. Alisjahbana has nothing to disclose.Conflict of interest: Dr. van Crevel has nothing to disclose. ER -